Veeva Systems Inc. (VEEV)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Veeva Systems Inc. (VEEV) trades at $192.74 with AI Score 92/100 (Grade A+). Veeva Systems Inc. provides cloud-based software solutions tailored for the life sciences industry. Market cap: $31.31B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026VEEV stock analysis for 2026: Analysts have set a consensus price target of $258.33 for Veeva Systems Inc., suggesting 34.0% upside from the current price of $192.74. The AI MoonshotScore is 92/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
VEEV: 6/8 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Veeva Systems Inc. (VEEV) Healthcare & Pipeline Overview
Veeva Systems Inc. delivers cloud-based software solutions for the life sciences industry, offering a suite of CRM, data, and content management applications. With a focus on regulatory compliance and operational efficiency, Veeva serves pharmaceutical, biotechnology, and healthcare companies globally, positioning itself as a key technology partner in the sector.
What Is the Investment Thesis for VEEV?
Veeva Systems Inc. presents a notable research candidate within the healthcare information services sector. With a market capitalization of $31.31B and a P/E ratio of 33.1, Veeva demonstrates strong financial performance. A gross margin of 75.5% and a profit margin of 28.4% highlight the company's operational efficiency and profitability. Key growth catalysts include the expansion of Veeva Vault into new therapeutic areas and the increasing adoption of Veeva Commercial Cloud solutions by pharmaceutical and biotechnology companies. The company's focus on regulatory compliance and data management within the life sciences industry positions it favorably amid increasing regulatory scrutiny. However, potential risks include competition from established players and the potential for slower growth in mature markets. The company's beta of 1.10 indicates moderate volatility relative to the market.
Based on FMP financials and quantitative analysis
VEEV Key Highlights
- Market capitalization of $31.31B reflects strong investor confidence in Veeva's market position and growth potential.
- P/E ratio of 33.1 indicates a premium valuation, reflecting expectations of continued earnings growth.
- Gross margin of 75.5% demonstrates Veeva's pricing power and efficient cost management in its software and services offerings.
- Profit margin of 28.4% underscores the company's ability to convert revenue into profit, showcasing operational excellence.
- Veeva's focus on cloud-based solutions aligns with the increasing demand for scalable and secure data management in the life sciences industry.
Who Are VEEV's Competitors?
VEEV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BDX Becton, Dickinson and Company | $158.08 | +3.39% | $57.27B | 72 |
| ARGX argenx SE | $939.68 | +3.32% | $58.15B | 49 |
| EW Edwards Lifesciences Corporation | $94.37 | +2.59% | $54.34B | 94 |
| IDXX IDEXX Laboratories, Inc. | $557.80 | +3.76% | $44.00B | 93 |
| CAH Cardinal Health, Inc. | $238.94 | +0.51% | $55.96B | 88 |
| CARL CARLSMED, INC. | $11.34 | -3.16% | $308.28M | 70 |
| HNGE Hinge Health, Inc. | $84.05 | -1.20% | $6.50B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VEEV's Key Strengths?
- Dominant market position in cloud-based solutions for the life sciences industry.
- Comprehensive suite of products and services covering various functional areas.
- Strong customer relationships and high customer retention rates.
- Experienced management team and a culture of innovation.
What Are VEEV's Weaknesses?
- Reliance on the life sciences industry, making it vulnerable to industry-specific downturns.
- Relatively high pricing compared to some competitors.
- Limited presence in certain emerging markets.
- Potential for slower growth in mature markets.
What Could Drive VEEV Stock Higher?
- Continued expansion of Veeva Vault into new therapeutic areas.
- Increasing adoption of Veeva Commercial Cloud solutions by pharmaceutical and biotechnology companies.
- Potential strategic partnerships and acquisitions to expand product portfolio and market reach.
- Global expansion into emerging markets, such as China and India.
- Development of AI-powered solutions for drug discovery and clinical trial optimization.
What Are the Key Risks for VEEV?
- Rich valuation — a P/E of 33.1 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Increasing competition from established players and new entrants in the cloud-based solutions market.
- Evolving regulatory landscape and compliance requirements in the life sciences industry.
- Potential for data breaches and security vulnerabilities in Veeva's cloud infrastructure.
- Economic downturns and reduced healthcare spending impacting demand for Veeva's solutions.
- Dependence on key personnel, including CEO Peter Gassner.
What Are the Growth Opportunities for VEEV?
- Expansion of Veeva Vault into New Therapeutic Areas: Veeva has the opportunity to expand the Veeva Vault platform into new therapeutic areas beyond its current focus. This includes areas such as oncology, cardiovascular diseases, and rare diseases. The market for cloud-based solutions in these therapeutic areas is estimated to be $5 billion by 2028, offering significant growth potential for Veeva. By tailoring Veeva Vault to meet the specific needs of these areas, Veeva can attract new customers and increase its market share.
- Increasing Adoption of Veeva Commercial Cloud: The increasing adoption of Veeva Commercial Cloud solutions by pharmaceutical and biotechnology companies presents a significant growth opportunity. The global market for CRM and commercial solutions in the life sciences industry is projected to reach $12 billion by 2027. Veeva can capitalize on this trend by enhancing its Commercial Cloud offerings with advanced analytics and AI-powered capabilities, attracting more customers seeking to improve their sales and marketing effectiveness.
- Strategic Partnerships and Acquisitions: Veeva can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. This includes partnering with data analytics companies, AI solution providers, and other technology vendors to integrate their capabilities into Veeva's platform. The market for strategic partnerships and acquisitions in the healthcare IT sector is estimated to be $8 billion by 2026. By carefully selecting partners and acquisition targets, Veeva can accelerate its growth and strengthen its competitive position.
- Global Expansion into Emerging Markets: Veeva has the opportunity to expand its presence in emerging markets, such as China, India, and Brazil. These markets are experiencing rapid growth in the life sciences industry, driven by increasing healthcare spending and a growing demand for advanced technologies. The market for cloud-based solutions in these emerging markets is projected to reach $4 billion by 2028. By establishing a strong presence in these markets, Veeva can tap into new revenue streams and diversify its geographic footprint.
- Development of AI-Powered Solutions: Veeva can leverage artificial intelligence (AI) and machine learning (ML) to develop innovative solutions that address the evolving needs of the life sciences industry. This includes AI-powered analytics for drug discovery, clinical trial optimization, and personalized medicine. The market for AI in healthcare is projected to reach $45 billion by 2027. By investing in AI research and development, Veeva can create new revenue streams and differentiate itself from competitors.
What Opportunities Does VEEV Have?
- Expansion into new therapeutic areas and functional areas.
- Strategic partnerships and acquisitions to expand product portfolio and market reach.
- Increased adoption of AI and machine learning in healthcare.
- Growing demand for cloud-based solutions in emerging markets.
What Threats Does VEEV Face?
- Increasing competition from established players and new entrants.
- Evolving regulatory landscape and compliance requirements.
- Potential for data breaches and security vulnerabilities.
- Economic downturns and reduced healthcare spending.
What Are VEEV's Competitive Advantages?
- High switching costs due to the mission-critical nature of Veeva's solutions.
- Strong brand reputation and industry expertise.
- Extensive customer network and data assets.
- Proprietary technology and intellectual property.
What Does VEEV Do?
Veeva Systems Inc., founded in 2007 and headquartered in Pleasanton, California, provides cloud-based software solutions specifically designed for the life sciences industry. Originally named Verticals onDemand, Inc., the company rebranded as Veeva Systems Inc. in April 2009, signaling its dedicated focus on the vertical market. Veeva's core offering is the Veeva Commercial Cloud, a comprehensive suite of software, data, and analytics solutions. This includes Veeva CRM and Veeva Medical CRM for customer relationship management, Veeva CLM for closed-loop marketing, Veeva Nitro for data warehousing, Veeva OpenData for healthcare professional data, Veeva Link for key opinion leader insights, Veeva Network for customer master data management, Veeva Crossix for marketing analytics, Veeva Data Cloud, and MyVeeva for Patients. Additionally, Veeva offers Veeva Vault, a cloud-based enterprise content and data management application that manages commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. Veeva serves a global clientele across North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company also provides professional and support services, including implementation, deployment planning, project management, requirements analysis, solution design, configuration, systems environment management, and technical consulting services.
What Products and Services Does VEEV Offer?
- Provides cloud-based software solutions for the life sciences industry.
- Offers Veeva Commercial Cloud, a suite of CRM, data, and analytics solutions.
- Provides Veeva Vault, a cloud-based enterprise content and data management application.
- Supports commercial functions, including sales and marketing, and medical content and communications.
- Supports research and development functions, such as clinical, regulatory, quality, and safety.
- Offers professional and support services, including implementation and deployment planning.
- Provides ongoing managed services, including outsourced systems administration.
How Does VEEV Make Money?
- Subscription-based revenue from Veeva Commercial Cloud and Veeva Vault.
- Professional services revenue from implementation, deployment, and consulting services.
- Support services revenue from ongoing maintenance and support.
- Data and analytics revenue from Veeva OpenData, Veeva Link, and Veeva Crossix.
What Industry Does VEEV Operate In?
Veeva Systems Inc. operates within the healthcare information services sector, which is experiencing robust growth driven by the increasing adoption of digital technologies in the life sciences industry. The market is characterized by stringent regulatory requirements, increasing data volumes, and a growing need for efficient data management solutions. Veeva competes with established players and niche providers, differentiating itself through its comprehensive suite of cloud-based solutions and its deep industry expertise. The global healthcare IT market is projected to reach $390 billion by 2026, presenting significant growth opportunities for Veeva.
Who Are VEEV's Key Customers?
- Pharmaceutical companies
- Biotechnology companies
- Medical device companies
- Contract research organizations (CROs)
Net buyingInsider Activity
Over the past six months, Veeva Systems Inc. insiders filed 15 SEC Form 4 transactions — 2 sales and 13 purchases. On net that is roughly 14K shares acquired (about $232K) — insiders putting money in tends to read as conviction.
FY2026 estForward Outlook
Wall Street analysts project Veeva Systems Inc. revenue of about $3.17B for fiscal 2026, with EPS near $7.94. The estimate reflects 21 contributing analysts.
8/8 beatsEarnings Track Record
Veeva Systems Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 7.4% above estimates on average.
F-Score 5/9Financial Health
Veeva Systems Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 12.65 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 13%Key Financial Metrics
Return on equity for Veeva Systems Inc. stands at 13.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.3%, showing how much profit it generates from its asset base. VEEV trades at a trailing price-to-earnings ratio of 33.08, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.74 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.1%, the inverse of the P/E and a quick read on earnings relative to price.
Veeva Systems Inc. (VEEV) Valuation Context
Valued at $31.31B, VEEV is classified as a large-cap stock. Relative to its peer group, VEEV's quantitative score of 92/100 is above the peer average of 79/100.
VEEV Revenue & Earnings Trend
In Q2 2026, VEEV generated $882.9M in top-line revenue, marking a sequential increase of 5.6%. The company recorded net income of $260.9M, with diluted EPS of $1.57. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, VEEV averaged $1.41 in diluted EPS.
Company Profile
Veeva Systems Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Pleasanton, US. The company is led by CEO Peter Gassner. VEEV has traded publicly since 2013.
VEEV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Veeva's strong relationships with major pharma companies suggest consistent revenue streams. Think of it like Oracle in the database world, but for life sciences.
- Insiders buying shares lately sends a strong signal they believe in the long-term growth. It's like when Bezos bought Amazon stock – confidence booster.
- Community buzz is generally positive, focusing on Veeva's expanding product suite. They're not a one-trick pony, unlike some SaaS companies.
- Veeva's focus on a niche market (life sciences) provides a competitive moat. Harder for new players to disrupt, similar to how ASML dominates lithography.
Bear Case
- Recent chatter highlights increasing competition in the CRM space for pharma. Salesforce is always looming, like Microsoft in the OS market.
- Some worry Veeva's growth may slow as the pharma market matures. The initial land grab is over; now it's about retention.
- Insider selling, even if planned, can spook investors and create negative sentiment. Perception matters, like when Musk sells Tesla shares.
- The community expresses concerns about potential overvaluation, making it vulnerable to market corrections. High P/E ratios can be a double-edged sword.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $883M | $261M | $1.57 |
| Q1 2026 | $836M | $244M | $1.45 |
| Q4 2025 | $811M | $236M | $1.41 |
| Q3 2025 | $789M | $200M | $1.20 |
Based on FMP financials and quantitative analysis
VEEV Latest News
-
8 Health Care Stocks Whale Activity In Today’s Session
benzinga · Jul 3, 2026
-
Michael Burry Buys the Dip in Four Tech Stocks He Sees as Bargains
benzinga · Jun 13, 2026
-
10 Health Care Stocks Whale Activity In Today's Session
benzinga · Jun 5, 2026
-
Veeva Systems Q1 Earnings Call Highlights
Yahoo! Finance: VEEV News · Jun 3, 2026
VEEV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VEEV.
Price Targets
Consensus target: $258.33
VEEV MoonshotScore
What does this score mean?
The MoonshotScore rates VEEV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
8 Health Care Stocks Whale Activity In Today’s Session
Michael Burry Buys the Dip in Four Tech Stocks He Sees as Bargains
10 Health Care Stocks Whale Activity In Today's Session
Veeva Systems Q1 Earnings Call Highlights
Latest Veeva Systems Inc. Analysis
Leadership: Peter Gassner
CEO
Peter Gassner is the CEO of Veeva Systems Inc. He has extensive experience in the software industry, having previously served as Senior Vice President of Technology at salesforce.com. Prior to that, he held leadership positions at PeopleSoft and IBM. Gassner holds a Bachelor of Science degree in Computer Science from Oregon State University. His deep understanding of cloud computing and enterprise software has been instrumental in Veeva's success.
Track Record: Under Peter Gassner's leadership, Veeva Systems Inc. has grown from a startup to a leading provider of cloud-based solutions for the life sciences industry. He has overseen the company's expansion into new markets and the development of innovative products, such as Veeva Vault and Veeva Commercial Cloud. Gassner has also fostered a strong company culture focused on customer success and innovation. Veeva's revenue and market capitalization have increased significantly during his tenure.
VEEV Healthcare Stock FAQ
What does Veeva Systems Inc. do?
Veeva Systems Inc. provides cloud-based software solutions for the global life sciences industry. Its core offerings include Veeva Commercial Cloud, which encompasses CRM, content management, and data solutions, and Veeva Vault, a unified platform for managing clinical, regulatory, and quality data. Veeva's solutions help pharmaceutical, biotechnology, and medical device companies streamline their operations, improve compliance, and accelerate product development. The company's focus on industry-specific needs and its commitment to innovation have made it a leading technology partner for life sciences organizations.
What do analysts say about VEEV stock?
Analyst consensus on VEEV stock is generally positive, reflecting the company's strong market position and growth prospects. Key valuation metrics include a P/E ratio of 33.1, which indicates a premium valuation. Analysts cite Veeva's consistent revenue growth, high gross margins, and recurring revenue model as positive factors. However, some analysts caution about potential risks, such as increasing competition and the potential for slower growth in mature markets. Overall, analysts expect Veeva to continue to grow its revenue and earnings in the coming years, driven by the increasing adoption of cloud-based solutions in the life sciences industry. This is a neutral summary of analyst sentiment, not a buy/sell recommendation.
What are the main risks for VEEV?
The main risks for Veeva Systems Inc. include increasing competition from established players and new entrants in the cloud-based solutions market, evolving regulatory landscape and compliance requirements in the life sciences industry, potential for data breaches and security vulnerabilities in Veeva's cloud infrastructure, economic downturns and reduced healthcare spending impacting demand for Veeva's solutions, and dependence on key personnel, including CEO Peter Gassner. These risks could negatively impact Veeva's revenue growth, profitability, and market share. The company's ability to mitigate these risks will be critical to its long-term success.
What are the key factors to evaluate for VEEV?
Veeva Systems Inc. (VEEV) holds an AI score of 92/100 (high). P/E: 33.1x vs the S&P 500's ~20-25x. Analysts target $258.33 (+34%). Not financial advice.
How frequently does VEEV data refresh on this page?
VEEV prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VEEV's recent stock price performance?
Veeva Systems Inc. (VEEV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Dominant market position in cloud-based solutions for the life sciences industry. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VEEV overvalued or undervalued right now?
Veeva Systems Inc. (VEEV) trades at 33.1x earnings. Analysts target $258.33 (+34%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying VEEV?
Before investing in Veeva Systems Inc. (VEEV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of 2026-05-10.